Skip to main content
. 2022 Sep 9;14(18):4386. doi: 10.3390/cancers14184386

Figure 1.

Figure 1

Alterations in both proto-oncogenes and tumor suppressor genes may lead to cancer development, but current personalized cancer medicine is mainly based on the inhibition of activating alterations. We propose to expand the scope of personalized cancer medicine by developing tumor suppressor protein-specific mimetic drugs that can partially or fully substitute the lost tumor suppressive function.